| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The FASEB Journal, Vol 11, 582-590, Copyright © 1997 by The Federation of American Societies for Experimental Biology
RESEARCH COMMUNICATIONS |
J Howl, U Langel, SR Hawtin, A Valkna, NJ Yarwood, K Saar and M Wheatley
School of Biochemistry, University of Birmingham, Edgbaston, U.K.
The aim of this study was to evaluate a variety of synthetic strategies pertinent to the development of chimeric analogs of the structurally divergent nonapeptide hormones arginine vasopressin (AVP) and bradykinin (BK). Single-chain peptides combining AVP and BK directly, AVP(1-9)-BK(1-9) or via a flexible aminohexanoic acid (epsilonAhx) linker, AVP(1-9)-epsilonAhx-BK(1-9), bind with relatively high affinity to the bovine kidney medulla B2a bradykinin receptor (B2a BKR). Significantly, amino-terminal extended chimeric analogs of BK, including AVP(1-9)-BK(1-9) and galanin(1-13)-BK(1-9), are functional B2 BKR agonists. These findings illustrate that chimeric peptides can activate G-protein-coupled receptors (GPCRs) in a manner analogous to that of endogenous monomeric agonists. Further development, combining the sequences of receptor subtype-selective antagonists, produced high- affinity chimeric antagonists of the V1a vasopressin receptor (V1a VPR) and the B2a BKR. We also determined the pharmacological characteristics of high-affinity chimeric hormone analogs derivatized with the membrane targeting function of mastoparan. Homodimers of an amino-terminal extended BK analog and a V1a-selective antagonist represent the first examples of new classes of B2 BKR and V1a VPR antagonists, respectively. These findings are discussed in relation to the GPCR binding site for small peptides and the development of novel biological probes and therapeutic agents.
This article has been cited by other articles:
|
|
 |
|
  M. Conner, S. R. Hawtin, J. Simms, D. Wootten, Z. Lawson, A. C. Conner, R. A. Parslow, and M. Wheatley Systematic Analysis of the Entire Second Extracellular Loop of the V1a Vasopressin Receptor: KEY RESIDUES, CONSERVED THROUGHOUT A G-PROTEIN-COUPLED RECEPTOR FAMILY, IDENTIFIED J. Biol. Chem., June 15, 2007; 282(24): 17405 - 17412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Hawtin, J. Simms, M. Conner, Z. Lawson, R. A. Parslow, J. Trim, A. Sheppard, and M. Wheatley Charged Extracellular Residues, Conserved throughout a G-protein-coupled Receptor Family, Are Required for Ligand Binding, Receptor Activation, and Cell-surface Expression J. Biol. Chem., December 15, 2006; 281(50): 38478 - 38488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Hawtin, V. J. Wesley, J. Simms, C. C. H. Argent, K. Latif, and M. Wheatley The N-Terminal Juxtamembrane Segment of the V1a Vasopressin Receptor Provides Two Independent Epitopes Required for High-Affinity Agonist Binding and Signaling Mol. Endocrinol., November 1, 2005; 19(11): 2871 - 2881. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Hawtin, V. J. Wesley, R. A. Parslow, J. Simms, A. Miles, K. McEwan, and M. Wheatley A Single Residue (Arg46) Located Within the N-Terminus of the V1a Vasopressin Receptor Is Critical for Binding Vasopressin But Not Peptide or Nonpeptide Antagonists Mol. Endocrinol., March 1, 2002; 16(3): 600 - 609. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
